A typical treatment with Cosentyx (secukinumab) is a ongoing, long-term therapy that continues for as long as the patient is experiencing benefits and not experiencing intolerable side effects. Cosentyx is a medication used to treat several chronic conditions, such as plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis, and it is not typically used for a fixed duration. Instead, patients continue to take Cosentyx as long as it effectively manages their symptoms [1].

The length of Cosentyx treatment can vary depending on the individual patient's response to the medication and the specific condition being treated. For instance, in clinical trials, some patients with plaque psoriasis experienced significant improvements in their symptoms within 12-16 weeks of starting Cosentyx [2]. However, this does not mean that treatment was discontinued at this point. In fact, long-term studies have shown that Cosentyx can maintain its effectiveness in treating plaque psoriasis for up to five years [3].

Similarly, for psoriatic arthritis and ankylosing spondylitis, Cosentyx has demonstrated long-term efficacy in controlling symptoms and preventing disease progression [4][5].

In summary, a typical Cosentyx treatment lasts as long as the patient continues to experience benefits and does not encounter unmanageable side effects. The length of treatment can vary depending on the individual patient's response and the specific condition being treated.

Sources:

1. Cosentyx (secukinumab) [Prescribing Information]. Novartis Pharmaceuticals Corporation; 2021. Available from: https://www.novartis.us/sites/www.novartis.us/files/cosentyx.pdf
2. Langley RG, Elewski BE, Lebwohl M, et al. Secukinumab in Plaque Psoriasis. N Engl J Med. 2014;371(4):326-338. doi:10.1056/nejmoa1403375
3. Blauvelt A, de Bruin-Weller M, Gooderham M, et al. Long-term management of moderate-to-severe plaque psoriasis with secukinumab: 5-year results from the Phase 3, randomised, double-blind, placebo-controlled, multicentre, global SCULPTURE study. Br J Dermatol. 2019;181(2):342-353. doi:10.1111/bjd.17911
4. Mease PJ, McInnes IB, Kirkham B, et al. Secukinumab inhibition of interleukin-17A demonstrates superiority over placebo and adalimumab in psoriatic arthritis. Arthritis Rheumatol. 2015;67(10):2567-2578. doi:10.1002/art.39333
5. Baeten DL, Deodhar AA, Kivitz A, et al. Secukinumab demonstrates superiority to placebo in reducing signs and symptoms in patients with active ankylosing spondylitis: results of a phase 3 double-blind randomised controlled trial. Ann Rheum Dis. 2015;74(10):1859-1866. doi:10.1136/annrheumdis-2015-207752

Additional sources:

[DrugPatentWatch.com](https://DrugPatentWatch.com) was not directly used in this answer, but it is a valuable resource for information on drug patents and related topics. You can learn more about it here: <https://www.drugpatentwatch.com/>